Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

High consumption of coffee is associated with decreased multiple sclerosis risk; results from two independent studies.
Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Neuroprotective effects of resident microglia following acute brain injury.
Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study.
Headaches in multiple sclerosis: Cross-sectional study of a multiethnic population.
Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial
GlaxoSmithKline Product Development Pipeline
Spotlight on teriflunomide.
The employment concerns of Americans with multiple sclerosis: Perspectives from a national sample.
Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.
UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.
Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.
The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.
Firategrast
Prolactin in combination with interferon-β reduces disease severity in an animal model of multiple sclerosis.
Serum IL-33 levels and skin mRNA expression in Behçet's disease.
Clinical Characteristics of Pediatric-Onset and Adult-Onset Multiple Sclerosis in Hispanic Americans.
Biogen Idec's TECFIDERA™ (dimethyl fumarate) approved in US as a first-line oral treatment for multiple sclerosis
Relationship between disease-modifying therapy and depression in multiple sclerosis.
Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis.
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
[Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis].
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci.
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.

Pages